Discount Code (0% Off) has been applied.
Customer Service (800) 854-7220
Free 3 Day Shipping on orders over $50
Make a Selection
(0) items
You have no items in your shopping cart.
Browse by Category

    Ask your Representatives to Sign Rep. Stewart / Carter Letter to FDA regarding office-use

    Ask your Representatives to Sign Rep. Stewart / Carter Letter to FDA regarding office-use

    On December 29, 2016, the Food & Drug Administration (FDA) issued a final Guidance for Industry (GFI) which continues to completely prohibit office-use compounding under state pharmacy laws. This guidance is a misinterpretation of the 2013 Drug Quality and Security Act (DQSA) regarding office-use compounding. Additionally, the FDA has unfortunately chosen to ignore broad and diverse stakeholder input, multiple congressional letters from both chambers, and clear directives in the House Report accompanying the FY2016 FDA appropriations legislation. This Guidance is VERY detrimental for patients and doctors to access compounded medications.

    Luckily, Congressmen Chris Stewart and Buddy Carter are leading an effort to gather Representative signatures on a letter to FDA regarding office-use compounding. The letter requests that the FDA immediately rescind this GFI and issue a proposed rule, with notice and stakeholder input as required by the Administrative Procedure Act, that is consistent with the DQSA and that allows for office-use compounding by state-licensed pharmacies where it is authorized by state pharmacy laws.

    We, McGuff Compounding Pharmacy Services, ask for your help to take action with us by clicking the link below to request the assistance of your congressman and senators to sign onto the letter to the FDA. This letter is being submitted to the FDA on March 31st, 2017 so time is of the essence.

    If you have any questions at all, please do not hesitate to ask! You may email us at or call us at 877-444-1133.

    Reference Material:

    Letter your Congressman will sign onto for the FDA

    Food & Drug Administration final Guidance for Industry – Compounded Medications

    Coronavirus (COVID-19)

    Due to the Coronavirus (COVID-19) outbreak worldwide, the global demand for some Personal Protective Equipment (PPE) is exceeding current supply availability.

    In addition, the manufacturing of the PPE and many other wound care/infection prevention products have been impacted by the global response to the Coronavirus. While you may see product availability reduction in the near-term, please be assured that we at McGuff Medical are continuing to work diligently to ensure an uninterrupted supply of products and alternative products to you.

    Additionally, in order to ensure healthcare providers have access to the PPEs they need, the McGuff Company is temporarily limiting PPEs to healthcare providers.

    As always, please feel free to reach out to our McGuff Customer Service team with any questions that you may have.

    Click here for updates regarding Coronavirus Pandemic and Your Supplies and a message from our President